We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Triptorelin is a gonadotropin releasing hormone (GnRH) agonist that is a potent inhibitor of the synthesis of testosterone (in men) and estrogen (in women) and is used to treat advanced prostate cancer.
CAT No: R1945
CAS No: 57773-63-4
Synonyms/Alias: TRIPTORELIN;57773-63-4;Triptoreline;Triptorelina;Arvekap;Triptorelinum;Triptodur;(D-Trp6)-GnRH;Triptorelin pamoate;Decapeptyl;tryptorelin;Diferelin;Trelstar;D-Tryptophan-LH-RH;Diphereline;pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2;UNII-9081Y98W2V;CHEBI:63633;CL 118532;CL-118532;CL 118,532;BIM 21003;Wy 42422;[D-Trp6]-LH-RH;Triptoreline [INN-French];Triptorelinum [INN-Latin];Triptorelina [INN-Spanish];AY-25650;DTXSID2048375;Pamorelin;Salvacyl;Trelstar depot;9081Y98W2V;5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide;Trelstar LA;(D-Trp6)-LH-RH;Triptoreline (INN-French);Triptorelinum (INN-Latin);Triptorelina (INN-Spanish);6-D-tryptophan-LH-RH;D-Trp-6-LH-RH;LHRH, Tryptophyl(6)-;Wy 42462;GnRH, Trp(6)-;LHRH, Trp(6)-;Detryptoreline;AY 25650;Trellasar;Moapar;Triptorelin [USAN:INN:BAN];Decapeptyl SR;Pamorelin LA;Triptorelin (swine);Wy-42462;D-Trp6-LHRH;Debio-8206;Triptorelin (USAN/INN);TRIPTORELIN (MART.);GTPL1177;SCHEMBL5079698;CHEMBL1201334;DTXCID8028349;SCHEMBL22289009;L02AE04;VXKHXGOKWPXYNA-PGBVPBMZSA-N;HMS2090C17;EX-A3857;BIM-21003;AKOS030213249;CS-5745;DB06825;NCGC00167301-01;NCGC00167301-02;AS-71149;BN-52014;DA-48936;HY-12551;CL-118,532;C75704;D06247;[D-Trp6]-LH-RH, >=97% (HPLC), powder;AB01275488-01;6-D-Tryptophanluteinizing Hormone-releasing Factor;A936467;EN300-18527985;pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH2;Q1992452;BRD-K62685538-001-01-7;(S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide;Glycinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolyl-;
Chemical Name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C64H82N18O13 |
M.W/Mr. | 1311.4 |
Sequence | One Letter Code:XHWSYWLRPG Three Letter Code:H-Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 |
Appearance | Solid powder |
Biological Activity | Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) peptide agonist that binds to the GnRH receptor. It inhibits the growth of DU145, LNCaP, and PC3 prostate and OVCAR-3 ovarian cancer cells. |
Target | Gonadotropin-releasing hormone (GnRH) |
Long-term Storage Conditions | Soluble in DMSO |
InChI | InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1 |
InChI Key | VXKHXGOKWPXYNA-PGBVPBMZSA-N |
Canonical SMILES | CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8 |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8 |
References | A total of 22 months' worth of data were analyzed (or 1 041 638 total items, monthly average 47 347 items). Goserelin; leuprorelin, and triptorelin are the medicines most used by total quantity in the study period. Simple descriptive statistics show that mean values have declined during the pandemic. The Interrupted Time Series (ARIMA Modeling) shows declining trends. Ravina Barrett, Robert Barrett, Kalyan Dhar, Gonadorelins adherence in prostate cancer: A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020) |
2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.